Novo Nordisk's China President Zhou to step down in March

Reuters01-30

UPDATE 1-<a href="https://laohu8.com/S/NVO">Novo Nordisk</a>'s China President Zhou to step down in March

Updates with context about Novo's China competition

BEIJING, Jan 30 (Reuters) - The longtime head of Novo Nordisk's NOVOb.CO China business will leave the company, the Danish drugmaker said on Friday, as it competes against Eli Lilly LLY.N and a growing number of local drugmakers in the world's second largest pharmaceutical market.

Christine Zhou, a senior vice president who has led the firm's operations in Taiwan, Hong Kong, Macau, and mainland China since 2018, will leave at the end of March, Novo said in a statement on its official WeChat account.

Zhou was in charge for rollouts of both its blockbuster diabetes drug Ozempic, approved in China in 2021, and later the obesity drug Wegovy. Novo has since faced off against emerging rivals in diabetes and obesity, including drugs from Lilly and Chinese drugmaker Innovent Biologics 1801.HK.

Earlier on Friday, another drugmaker, China's Sciwind Biosciences, said its own type 2 diabetes treatment was also approved in the country, another potential challenge to Novo's share of the major market, and this year a local patent for the active ingredient in Wegovy and Ozempic is also set to expire.

(Reporting by Ethan Wang and Ryan Woo in Beijing, and Andrew Silver in Shanghai; Editing by Jacqueline Wong and Tomasz Janowski)

((Ethan.Wang@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2607001590?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-30 17:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2607001590","market":"fut","top_or_hot":-1,"title":"Novo Nordisk's China President Zhou to step down in March","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>UPDATE 1-<a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s China President Zhou to step down in March</title></head><body><p>Updates with context about Novo's China competition</p><p>\n<span>BEIJING, Jan 30 (Reuters)</span><span> - </span>The longtime head of Novo Nordisk's <span>NOVOb.CO</span> China business will leave the company, the Danish drugmaker said on Friday, as it competes against Eli Lilly <span>LLY.N</span> and a growing number of local drugmakers in the world's second largest pharmaceutical market.</p><p>Christine Zhou, a senior vice president who has led the firm's operations in Taiwan, Hong Kong, Macau, and mainland China since 2018, will leave at the end of March, Novo said in a statement on its official WeChat account.</p><p>Zhou was in charge for rollouts of both its blockbuster diabetes drug Ozempic, <span>approved in China in 2021,</span> and later the obesity drug Wegovy. Novo has since <span>faced off</span> against emerging rivals in diabetes and obesity, including drugs from Lilly and Chinese drugmaker <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics</a> <span>1801.HK</span>.</p><p>Earlier on Friday, another drugmaker, China's Sciwind Biosciences, said its own type 2 diabetes treatment was also <span>approved </span>in the country, another potential challenge to Novo's share of the major market, and this year a local patent for the active ingredient in Wegovy and Ozempic is also set to expire. </p><p> (Reporting by Ethan Wang and Ryan Woo in Beijing, and Andrew Silver in Shanghai; Editing by Jacqueline Wong and Tomasz Janowski)</p><p> ((Ethan.Wang@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk's China President Zhou to step down in March</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk's China President Zhou to step down in March\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-30 17:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>UPDATE 1-<a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s China President Zhou to step down in March</title></head><body><p>Updates with context about Novo's China competition</p><p>\n<span>BEIJING, Jan 30 (Reuters)</span><span> - </span>The longtime head of Novo Nordisk's <span>NOVOb.CO</span> China business will leave the company, the Danish drugmaker said on Friday, as it competes against Eli Lilly <span>LLY.N</span> and a growing number of local drugmakers in the world's second largest pharmaceutical market.</p><p>Christine Zhou, a senior vice president who has led the firm's operations in Taiwan, Hong Kong, Macau, and mainland China since 2018, will leave at the end of March, Novo said in a statement on its official WeChat account.</p><p>Zhou was in charge for rollouts of both its blockbuster diabetes drug Ozempic, <span>approved in China in 2021,</span> and later the obesity drug Wegovy. Novo has since <span>faced off</span> against emerging rivals in diabetes and obesity, including drugs from Lilly and Chinese drugmaker <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics</a> <span>1801.HK</span>.</p><p>Earlier on Friday, another drugmaker, China's Sciwind Biosciences, said its own type 2 diabetes treatment was also <span>approved </span>in the country, another potential challenge to Novo's share of the major market, and this year a local patent for the active ingredient in Wegovy and Ozempic is also set to expire. </p><p> (Reporting by Ethan Wang and Ryan Woo in Beijing, and Andrew Silver in Shanghai; Editing by Jacqueline Wong and Tomasz Janowski)</p><p> ((Ethan.Wang@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2242644610.SGD","symbol_name":"Fidelity China Innovation A-ACC-SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nL6N3YV0I7:1","article_id":"2607001590","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2607001590","pubTimestamp":1769766370,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"UPDATE 1-Novo Nordisk's China President Zhou to step down in MarchUpdates with context about Novo's China competition. BEIJING, Jan 30  - The longtime head of Novo Nordisk's NOVOb.CO China business will leave the company, the Danish drugmaker said on Friday, as it competes against Eli Lilly LLY.N and a growing number of local drugmakers in the world's second largest pharmaceutical market.Christine Zhou, a senior vice president who has led the firm's operations in Taiwan, Hong Kong, Macau, and mainland China since 2018, will leave at the end of March, Novo said in a statement on its official WeChat account.Zhou was in charge for rollouts of both its blockbuster diabetes drug Ozempic, approved in China in 2021, and later the obesity drug Wegovy. Novo has since faced off against emerging rivals in diabetes and obesity, including drugs from Lilly and Chinese drugmaker Innovent Biologics 1801.HK.Earlier on Friday, another drugmaker, China's Sciwind Biosciences, said its own type 2 diabetes ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1161":"生物科技","BK1583":"高瓴概念","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","BK1589":"北水核心资产","01801":"信达生物","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC"},"translate_title":"诺和诺德中国区总裁周将于三月辞职","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":0.9},"content_text":"UPDATE 1-Novo Nordisk's China President Zhou to step down in MarchUpdates with context about Novo's China competition\nBEIJING, Jan 30 (Reuters) - The longtime head of Novo Nordisk's NOVOb.CO China business will leave the company, the Danish drugmaker said on Friday, as it competes against Eli Lilly LLY.N and a growing number of local drugmakers in the world's second largest pharmaceutical market.Christine Zhou, a senior vice president who has led the firm's operations in Taiwan, Hong Kong, Macau, and mainland China since 2018, will leave at the end of March, Novo said in a statement on its official WeChat account.Zhou was in charge for rollouts of both its blockbuster diabetes drug Ozempic, approved in China in 2021, and later the obesity drug Wegovy. Novo has since faced off against emerging rivals in diabetes and obesity, including drugs from Lilly and Chinese drugmaker Innovent Biologics 1801.HK.Earlier on Friday, another drugmaker, China's Sciwind Biosciences, said its own type 2 diabetes treatment was also approved in the country, another potential challenge to Novo's share of the major market, and this year a local patent for the active ingredient in Wegovy and Ozempic is also set to expire.  (Reporting by Ethan Wang and Ryan Woo in Beijing, and Andrew Silver in Shanghai; Editing by Jacqueline Wong and Tomasz Janowski) ((Ethan.Wang@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2607001590","isCrawlerRequest":true}